When should FDG‐PET be used in the modern management of lymphoma?
暂无分享,去创建一个
[1] H. Eich,et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). , 2014, International journal of radiation oncology, biology, physics.
[2] O. Casasnovas,et al. In Newly Diagnosed Diffuse Large B-Cell Lymphoma, Determination of Bone Marrow Involvement with 18F-FDG PET/CT Provides Better Diagnostic Performance and Prognostic Stratification Than Does Biopsy , 2013, The Journal of Nuclear Medicine.
[3] M. Federico,et al. The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] S. Barrington,et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. , 2013, Blood.
[5] R. Hicks,et al. Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy , 2013, British Journal of Cancer.
[6] K. Ardeshna,et al. A response-adjusted PET-based transplantation strategy in primary resistant and relapsed Hodgkin Lymphoma , 2013, Leukemia.
[7] H. Tilly,et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[8] J. Rowe,et al. Strikingly high false positivity of surveillance FDG‐PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era , 2013, American journal of hematology.
[9] Stephane Chauvie,et al. International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers , 2013, The Journal of Nuclear Medicine.
[10] J. Min,et al. Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era , 2013, Annals of Hematology.
[11] A. Zelenetz,et al. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma , 2013, Leukemia & lymphoma.
[12] A. López-Guillermo,et al. Interim FDG PET/CT as a prognostic factor in diffuse large B-cell lymphoma , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[13] B. Cheson. Hodgkin lymphoma: protecting the victims of our success. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Salles,et al. Impact of [(18)F]fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: a prospective study from the Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Radford,et al. Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial , 2012 .
[16] J. Raemaekers,et al. Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma , 2012 .
[17] M. Bøgsted,et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] R. Bouabdallah,et al. Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin’s lymphoma responding to prior salvage therapy , 2012, Haematologica.
[19] H. Amthauer,et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial , 2012, The Lancet.
[20] S. Ferrero,et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. , 2012, Blood.
[21] A. Zelenetz,et al. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma. , 2012, Blood.
[22] C. Copie-Bergman,et al. Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] H. Eich,et al. Role of [18F]-fluoro-2-deoxy-d-glucose positron emission tomography in early and late therapy assessment of patients with advanced Hodgkin lymphoma treated with bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine and prednisone , 2012, Leukemia & lymphoma.
[24] Andrew Homb,et al. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[25] T. Habermann,et al. Patients Enrolled in the Gimema Lal 0496 Protocol Presentation and Correlation with Response to Induction Treatment in Adult T-cell Acute Lymphoblastic Leukemia: Biologic Profile At , 2005 .
[26] J. Coya,et al. Diagnostic value of CT, PET and combined PET/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma. , 2011, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[27] P. Zinzani. PET in T-Cell Lymphoma , 2011, Current hematologic malignancy reports.
[28] M. Hutchings. Pre-transplant positron emission tomography/computed tomography (PET/CT) in relapsed Hodgkin lymphoma: time to shift gears for PET-positive patients? , 2011, Leukemia & lymphoma.
[29] M. Trněný,et al. Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma , 2011, Leukemia & lymphoma.
[30] G. Salles,et al. Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] B. Coiffier,et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. , 2011, Blood.
[32] Yen-Kung Chen,et al. F-18 FDG PET for Evaluation of Bone Marrow Involvement in Non-Hodgkin Lymphoma: A Meta-analysis , 2011, Clinical nuclear medicine.
[33] Sang-We Kim,et al. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP , 2011, Annals of Hematology.
[34] R. Coleman,et al. Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma , 2011, Bone Marrow Transplantation.
[35] J. Min,et al. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. , 2011, European journal of cancer.
[36] A. Zelenetz,et al. FDG-PET in the staging and prognosis of T-cell lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] I. Steffen,et al. Evaluation of interim PET response criteria in paediatric Hodgkin's lymphoma--results for dedicated assessment criteria in a blinded dual-centre read. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] R. Gascoyne,et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] A. LaCasce,et al. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] H. Johnsen,et al. Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center , 2011, Leukemia & lymphoma.
[41] Ö. Kapucu,et al. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival , 2011, Annals of Hematology.
[42] P. Marsden,et al. Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[43] M. Baccarani,et al. Midtreatment 18F‐fluorodeoxyglucose positron‐emission tomography in aggressive non‐Hodgkin lymphoma , 2011, Cancer.
[44] R. Houot,et al. 18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[45] Andrew Homb,et al. 18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation , 2011, The Journal of Nuclear Medicine.
[46] C. Bodet-Milin,et al. Prognostic value of interim FDG PET/CT in Hodgkin’s lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[47] O. Paltiel,et al. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma , 2011, Annals of Hematology.
[48] R. Miceli,et al. Pretransplantation [18‐F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non‐Hodgkin lymphoma undergoing reduced‐intensity conditioning followed by allogeneic stem cell transplantation , 2010, Cancer.
[49] I. Riphagen,et al. Added Value of Baseline 18F-FDG Uptake in Serial 18F-FDG PET for Evaluation of Response of Solid Extracerebral Tumors to Systemic Cytotoxic Neoadjuvant Treatment: A Meta-Analysis , 2010, The Journal of Nuclear Medicine.
[50] J. S. Júnior,et al. 18F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma , 2010, The Journal of Nuclear Medicine.
[51] A. D. Van den Abbeele,et al. Surveillance imaging of Hodgkin lymphoma patients in first remission , 2010, Cancer.
[52] M. Gönen,et al. Characterization of T-cell lymphomas by FDG PET/CT. , 2010, AJR. American journal of roentgenology.
[53] A. Gallamini. Positron emission tomography scanning: a new paradigm for the management of Hodgkin’s lymphoma , 2010 .
[54] T. Nihashi,et al. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. , 2010, The oncologist.
[55] J. Radford,et al. Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[56] S. Mackinnon,et al. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma. , 2010, Blood.
[57] J. C. Meneghetti,et al. Cost effectiveness of positron emission tomography in patients with Hodgkin's lymphoma in unconfirmed complete remission or partial remission after first-line therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] U. Tateishi,et al. SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma , 2010, Leukemia & lymphoma.
[59] Ora Israel,et al. 18F-FDG Avidity in Lymphoma Readdressed: A Study of 766 Patients , 2010, Journal of Nuclear Medicine.
[60] W. Oyen,et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[61] K. Jöckel,et al. Positron emission tomography guided therapy of aggressive non-Hodgkin lymphomas--the PETAL trial. , 2009 .
[62] A. D. Van den Abbeele,et al. CT and PET/CT findings of T-cell lymphoma. , 2009, AJR. American journal of roentgenology.
[63] J. Raemaekers,et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[64] P. Gaulard,et al. Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[65] A. Rahmouni,et al. Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy , 2009, Journal of Nuclear Medicine.
[66] Michel Meignan,et al. Report on the First International Workshop on interim-PET scan in lymphoma , 2009, Leukemia & lymphoma.
[67] J. Leonard,et al. Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] T. Pavlík,et al. Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma? , 2008, Clinical lymphoma & myeloma.
[69] R. Hicks,et al. FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY ON STAGING AND MANAGEMENT OF EARLY-STAGE FOLLICULAR NON-HODGKIN LYMPHOMA , 2022 .
[70] M. Mancini,et al. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma , 2008, La radiologia medica.
[71] N. Magné,et al. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[72] Emmanuel Itti,et al. Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis , 2007, Journal of Nuclear Medicine.
[73] T. Akhurst,et al. Limitations of CT During PET/CT , 2007, Journal of Nuclear Medicine.
[74] F. d'Amore,et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] M. Kojima,et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. , 2007, Cancer.
[76] S. Pileri,et al. Histological verification of positive positron emission tomography findings in the follow-up of patients with mediastinal lymphoma. , 2007, Haematologica.
[77] Sigrid Stroobants,et al. Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] Klemens Scheidhauer,et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] G. Salles,et al. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] P. Veit-Haibach,et al. Cost-effective therapy remission assessment in lymphoma patients using 2-[fluorine-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography: is an end of treatment exam necessary in all patients? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[81] C. Portlock. FDG-PET after two cycles of chemotherapy predicts treatment failure and Progression-free survival in Hodgkin’s lymphoma , 2006 .
[82] T. Nazeer,et al. Role of fluorine‐18 fluoro‐deoxyglucose positron emission tomography scan in the evaluation and follow‐up of patients with low‐grade lymphomas , 2006, Cancer.
[83] J. Matthews,et al. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement , 2006, European journal of haematology.
[84] M. O'Doherty,et al. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[85] Emmanuel Itti,et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. , 2005, Blood.
[86] Y. Erdi,et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] J. Vose,et al. Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] N. Mikhaeel,et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[89] Thomas F Hany,et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? , 2004, Radiology.
[90] G. Cook,et al. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. , 2004, Seminars in nuclear medicine.
[91] B. Beuthien-Baumann,et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma , 2004, British Journal of Cancer.
[92] A. Alavi,et al. Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.
[93] M. O'Doherty,et al. Limitations of PET for imaging lymphoma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[94] P. Dupont,et al. Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[95] P. Dupont,et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[96] S. Hain,et al. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: influence on patient management in a single institution. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[97] M. O'Doherty,et al. PET scanning and the human immunodeficiency virus-positive patient. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[98] M. Maisey,et al. FDG‐PET screening for cerebral metastases in patients with suspected malignancy , 1996, Nuclear medicine communications.
[99] F. d'Amore,et al. Patient-reported symptoms are still the single most important factor for detecting lymphoma relapse , 2013 .
[100] M. Baccarani,et al. Early interim 18F-FDG PET in Hodgkin’s lymphoma: evaluation on 304 patients , 2011, European Journal of Nuclear Medicine and Molecular Imaging.
[101] M. Mancini,et al. Role of whole-body (18F) fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non-Hodgkin lymphoma , 2009 .
[102] Martin Hutchings,et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.
[103] A. Nagler,et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[104] F. d'Amore,et al. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. , 2006, Haematologica.
[105] Y. Lacasse,et al. Cost-effectiveness of positron emission tomography for the management of potentially operable non-small cell lung cancer in Quebec. , 2005, Canadian respiratory journal.
[106] Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. Administration of Radioactive Substances Advisory Committee. , 2000, Nuclear medicine communications.